Sterility testing of minimally manipulated cord blood products: Validation of growth-based automated culture systems

Transfusion

Volumn 53, Issue 12, 2013, Pages 3251-3261

  Akel, Salem ^a   Lorenz, Joan ^a   Regan, Donna ^a  

^a SSM Cardinal Glennon Children's Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINOMYCES; ACTINOMYCES TURICENSIS; ARTICLE; ASPERGILLUS NIGER; BACILLUS SUBTILIS; BACTERIUM CULTURE; BACTEROIDES FRAGILIS; BLOOD ANALYSIS EQUIPMENT; BLOOD CULTURE; CANDIDA ALBICANS; CLOSTRIDIUM; CLOSTRIDIUM SUBTERMINALE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLONY FORMING UNIT; CONTROLLED STUDY; CULTURE MEDIUM; ESCHERICHIA COLI; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOOD AND DRUG ADMINISTRATION; FUNGUS CULTURE; FUNGUS GROWTH; INOCULATION; MICROBIAL GROWTH; MICROORGANISM DETECTION; NONHUMAN; PEPTOSTREPTOCOCCUS; PEPTOSTREPTOCOCCUS ASACCHAROLYTICUS; PROPIONIBACTERIUM ACNES; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; UMBILICAL CORD BLOOD; VALIDATION PROCESS; VALIDATION STUDY;

CULTURE MEDIA; FETAL BLOOD; HUMANS; INFECTION CONTROL;

EID: 84890432559     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12229     Document Type: Article

References (29)

1. US Food and Drug Administration. General Biologics Standards (21 CFR parts 600, 610 and 680) and Sterility Testing (section 610. 12). 2008.
2. United States Pharmacopeia. United States Pharmacopeia 28 and National Formulary 23 (USP 28 NF 23) 2005; Sterility Tests, General Chapter 71, 1-13.
3. US Food and Drug Administration. Draft guidance for industry. Validation of growth-based rapid microbiological methods for sterility testing of cellular and gene therapy products. Washington, DC: US Department of Health and Human Services; 2008.
4. United States Pharmacopeia. General Information Chapter <1223>, Validation of alternative microbiological methods. USP 32-NF27, U.S. Pharmacopeia Convention. Rockville, Maryland; 2009.
5. Food and Drug Administration. Amendments to Sterility Test Requirements for Biological Products. Proposed Rule. 21 CFR Parts 600, 610, and 680 [Docket No. FDA-2011-N-0080] 2011; 76 36019-36027.
6. Food and Drug Administration. Amendments to Sterility Test Requirements for Biological Products Final Rule. 21 CFR Parts 600, 610, and 680 [Docket No. FDA-2011-N-0080] 2012; 77: 26162-26175.
7. Khuu HM, Stock F, McGann M, Carter CS, Atkins JW, Murray PR, Read EJ,. Comparison of automated culture systems with a CFR/USP-compliant method for sterility testing of cell-therapy products. Cytotherapy 2004; 6: 183-195.
8. Khuu HM, Patel N, Carter CS, Murray PR, Read EJ,. Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method. Transfusion 2006; 46: 2071-2082.
9. Riedel S, Junkins A, Stamper PD, Cress G, Widness JA, Doern GV,. Comparison of the Bactec 9240 and BacT/Alert blood culture systems for evaluation of placental cord blood for transfusion in neonates. J Clin Microbiol 2009; 47: 1645-1649.
10. Alonso JM III, Regan DM, Johnson CE, Oliver DA, Fegan R, Lasky LC, Wall DA,. A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences. Cytotherapy 2001; 3: 429-433.
11. Kurtzberg J, Fraser J, Cairo M, Baxter-Lowe L, Cohen G, Carter S, Kernan N,. Results of the cord blood transplantation (COBLT) study unrelated donor banking program. Transfusion 2005; 45: 842-855.
12. Parveen S, Kaur S, David SA, Kenney JL, McCormick WM, Gupta RK,. Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products. Vaccine 2011; 29: 8012-8023.
13. Kielpinski G, Prinzi S, Duguid J, du Moulin G,. Roadmap to approval: use of an automated sterility test method as a lot release test for Carticel, autologous cultured chondrocytes. Cytotherapy 2005; 7: 531-541.
14. Spaargaren J, van Boven CPA, Voorn GP,. Effectiveness of resins in neutralizing antibiotic activities in Bactec Plus Aerobic/F culture media. J Clin Microbiol 1998; 36: 3731-3733.
15. Jorgensen JH, Mirrett S, McDonald LC, Murray PR, Weinstein MP, Fune J, Trippy CW, Masterson M, Reller LB,. Controlled clinical laboratory comparison of BACTEC plus aerobic/F resin medium with BacT/Alert aerobic FAN medium for detection of bacteremia and fungemia. J Clin Microbiol 1997; 35: 53-58.
16. Vetter E, Torgerson C, Feuker A, Hughes J, Harmsen S, Schleck C, Horstmeier C, Roberts G, Cockerill F 3rd,. Comparison of the BACTEC MYCO/F Lytic bottle to the isolator tube, BACTEC Plus Aerobic F/bottle, and BACTEC Anaerobic Lytic/10 bottle and comparison of the BACTEC Plus Aerobic F/bottle to the Isolator tube for recovery of bacteria, mycobacteria, and fungi from blood. J Clin Microbiol 2001; 39: 4380-4386.
17. Flayhart D, Borek AP, Wakefield T, Dick J, Carroll KC,. Comparison of BACTEC PLUS blood culture media to BacT/Alert FA blood culture media for detection of bacterial pathogens in samples containing therapeutic levels of antibiotics. J Clin Microbiol 2007; 45: 816-821.
18. Rohner P, Pepey B, Auckenthaler R,. Advantage of combining resin with lytic BACTEC blood culture media. J Clin Microbiol 1997; 5: 2634-2638.
19. Murray PR,. Growth of clinical isolates of anaerobic bacteria on agar media: effects of media composition, storage conditions, and reduction under anaerobic conditions. J Clin Microbiol 1978; 8: 708-714.
20. Zwietering MH, Jongenburger I, Rombouts FM, van't Riet K,. Modeling of the bacterial growth curve. Appl Environ Microbiol 1990; 56: 1875-1881.
21. Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D, Kapoor N, Guinan EC, Feig SA, Wagner EL, Kernan NA,. COBLT Steering Committee Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112: 4318-4327.
22. Rocha V, Locatelli F,. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41: 207-214.
23. Basford C, Forraz N, Habibollah S, Hanger K, McGuckin CP,. Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation. Cell Prolif 2009; 42: 751-761.
24. Clark P, Trickett A, Stark D, Vowels M,. Factors affecting microbial contamination rate of cord blood collected for transplantation. Transfusion 2012; 52: 1770-1777.
25. Rosa C, Araujo R, Rodrigues AG, Pinto-de-Sousa MI, Pina-Vaz C,. Detection of Aspergillus species in BACTEC blood cultures. J Med Microbiol 2011; 60: 1467-1471.
26. Lee Y, Thrupp L, Owens J, Cesario T, Shanbrom E,. Bactericidal activity of citrate against Gram-positive cocci. Lett Appl Microbiol 2001; 33: 349-351.
27. Richards RME, Xing DKL, King TP,. Activity of p-aminobenzoic acid compared with other organic acids against selected bacteria. J Appl Microbiol 1995; 78: 209-215.
28. Weinburg RS, Galperin Y, Liu L, Wang G, Corvina T, Katz Y, Straus D,. Discarded plasma may not be a good surrogate for detection of microbial contamination in final hematopoietic progenitor cell (HPC), cord blood products. Transfusion 2011; 51 (3S Suppl): SP496.
29. Chapin K, Lauderdale TL,. Comparison of Bactec 9240 and Difco ESP blood culture systems for detection of organisms from vials whose entry was delayed. J Clin Microbiol 1996; 34: 543-549.